Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00510614
Other study ID # PRO07030019
Secondary ID
Status Completed
Phase Phase 0
First received August 1, 2007
Last updated February 16, 2011
Start date October 2007
Est. completion date September 2009

Study information

Verified date February 2011
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This research study is being done to evaluate the use of an oral (by mouth) medication called tinidazole to initially treat BV and then to see if additional treatment with tinidazole keeps women from getting this infection back within 3 months. Tinidazole is currently approved by the United States Food and Drug Administration (FDA) to treat bacterial vaginosis (BV).

This study will evaluate the use of tinidazole to treat a woman's current BV infection and then will look at using tinidazole as a suppressive treatment (taking medication regularly to attempt to decrease the "bad" bacteria from growing back). The suppressive treatment phase will include using tinidazole twice a week compared to using placebo twice a week and then following women for recurrence of BV. The purpose of this study is to determine if tinidazole suppression will prevent BV from coming back within 3 months of treatment.

The investigators hypothesize that women with a history of recurrent bacterial vaginosis who are randomized to a suppressive regimen (a dose of medication given on a regular basis to attempt to control the bacteria that causes bacterial vaginosis) of tinidazole will have lower recurrence rates and a longer time to recurrence of bacterial vaginosis when compared to those women randomized to placebo.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date September 2009
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Age 18-45 at time of enrollment.

2. Recurrent BV as defined by:

- 2 previously documented diagnoses of BV in the past 6 months or

- 3 previously documented diagnoses of BV in the past year

3. Non-pregnant, non-lactating.

4. Premenopausal.

5. Presence of bacterial vaginosis at the enrollment visit using Amsel Criteria (at least 3 of 4):

- Presence of homogenous vaginal discharge

- pH of vaginal secretions of > 4.7

- Presence of a positive "whiff" test of the vaginal secretions upon mixing with 10% KOH

- Presence of > 20% clue cells on saline microscopy

6. Willingness to undergo randomization to a possible placebo arm (for suppressive therapy).

7. Ability to undergo informed consent.

8. Willingness to refrain from use of any intravaginal products (including douching, contraceptive spermicides, creams, gels, foams).

9. Currently using an acceptable method of birth control (such as a hormonal method including oral contraceptives, Depo Provera, Ortho Evra, abstinence x 60 days, consistent condom use, surgically sterile, lesbian orientation).

10. Willing to refrain from alcohol consumption during use of study medication and three days following completion of medication (which includes the 10 day open label treatment and the entire 3 month suppressive phase of treatment).

Exclusion Criteria:

1. Known active sexually transmitted infection at the time of enrollment with C. trachomatis, N. gonorrhoeae, T. vaginalis, or active (symptomatic) vulvovaginal candidiasis.

2. Current use of anticoagulants/blood thinners (i.e. warfarin, coumadin, heparin).

3. Current use of any of the following medications: lithium, fluorouracil, anticonvulsant/seizure medications, Questran (cholestyramine) or CYP3A4 inducer/inhibitors (i.e. phenobarbital, rifampin, phenytoin, fosphenytoin).

4. Use of Antabuse (disulfiram) currently or within the past 2 weeks.

5. Allergy to metronidazole or tinidazole (related drugs with likely cross-over allergy potential).

6. Use of any antibiotics (oral or vaginal) in the past 7 days.

7. Current use of an IUD, Nuva Ring.

8. Known immunosuppressive condition (i.e. HIV, end-stage renal disease, currently-treated diabetes mellitus, etc.) or on immunosuppressive medications [i.e. steroids, cyclosporine, Protopic (tacrolimus), immunomodulators].

9. Participation in an investigational drug study within the past 30 days.

10. Any condition which in the opinion of the investigator would impose a health risk to the subject or interfere with the evaluation of the study medication or procedures.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Intervention

Drug:
tinidazole
1 gram twice weekly for 12 weeks
Placebo
one pill twice weekly for 12 weeks

Locations

Country Name City State
United States Magee-Womens Hospital of UPMC Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
University of Pittsburgh Mission Pharmacal

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in the proportion of women clinically cured at each visit between the two therapy arms will be evaluated using Fisher's-exact test. at each study visit No
Secondary Kaplan-Meier product-limit estimation will be used to obtain estimates of the median time to BV recurrence. at each study visit No
See also
  Status Clinical Trial Phase
Completed NCT03930745 - Suppression Of Bacterial Vaginosis (BV) [SUBVert] Phase 2
Completed NCT02863536 - A Study of the New Medical Device Polybactum® N/A
Completed NCT03187457 - PreFem: "What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?" N/A
Recruiting NCT02185456 - Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Phase 0
Completed NCT02150655 - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Phase 0
Completed NCT01450462 - Vitamin D and Sexual Health N/A
Recruiting NCT01558388 - Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Phase 4
Not yet recruiting NCT00889356 - Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Phase 3
Completed NCT01471457 - Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis Phase 2/Phase 3
Completed NCT00545181 - Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial N/A
Completed NCT00556179 - Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Phase 4
Completed NCT02236156 - Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Phase 3
Not yet recruiting NCT05434104 - The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study N/A
Completed NCT01335373 - Observational Program Neo-Penotran® Forte N/A
Completed NCT00752193 - Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System. N/A
Active, not recruiting NCT00536848 - The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients Phase 2/Phase 3
Suspended NCT00207480 - Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women Phase 1
Recruiting NCT05278130 - Serial Screening and Treatment of Bacterial Vaginosis Trial N/A
Completed NCT02905890 - The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Phase 4
Recruiting NCT06135974 - Vaginal lIve Biotherapeutic RANdomized Trial Early Phase 1